charged to identify the child and family at risk to intercede to prevent trouble.

And we are involved in many more major problems: regionalization, the impact of malpractice on quality and cost of care, ethics of experimentation and prolongation of life, quality of care, peer review, accountability, financing medical education, research, and health care, continuing medical education, relicensure and recertification—the list is long.

The Academy and pediatricians are respected for we with honesty, humility, and concern indicate the inadequacies in child health care. Together we shall continue to try to resolve constantly changing child health needs. We truly cannot express adequate appreciation to our dedicated staff. We cannot as an organization or as Fellows express adequate appreciation to the individual pediatricians who have given countless hours of service to develop and implement the programs which I have enumerated in this report.

Thanks to all of you, this has been a proud year.
Thank you for letting me be your President.
And thank you—for sharing the excitement and responsibility of this honor.

Committee on Neoplastic Diseases

Is Liver Cancer Induced by Treating Aplastic Anemia With Androgenic Agents?

Pediatricians who use androgenic anabolic agents, such as oxymetholone, should be aware of recent evidence that primary liver neoplasia has developed in at least eight patients under treatment for aplastic anemia. The risk of liver cancer may be higher in Fanconi’s anemia (four cases) than in other forms of aplastic anemia. A causal relation is not yet certain. The underlying disease itself may have hepatic neoplasia as a complication, which becomes apparent only when survival is extended by drugs or other forms of therapy. Liver neoplasia has not been reported among athletes who use androgenic anabolic steroids to build up their musculature.

If these steroids are used, careful palpation of the abdomen should be done at each examination, for the earliest possible detection of hepatic masses. In one case reported to date, the tumor regressed when administration of the drug was discontinued.

REFERENCES
Committee on Neoplastic Diseases: Is Liver Cancer Induced by Treating Aplastic Anemia With Androgenic Agents?
Frederic N. Silverman, Giulio J. D'Angio, Inta J. Ertel, Donald J. Fernbach, Edwin N. Forman, Joseph H. Kushner, M. Eugene Lahey, Willam G. Thurman, Barbara Jones and Robert W. Miller
*Pediatrics* 1974;53;764

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at:</th>
<th><a href="http://pediatrics.aappublications.org/content/53/5/764">http://pediatrics.aappublications.org/content/53/5/764</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:</td>
<td><a href="http://www.aappublications.org/site/misc/Permissions.xhtml">http://www.aappublications.org/site/misc/Permissions.xhtml</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online:</td>
<td><a href="http://www.aappublications.org/site/misc/reprints.xhtml">http://www.aappublications.org/site/misc/reprints.xhtml</a></td>
</tr>
</tbody>
</table>
Committee on Neoplastic Diseases: Is Liver Cancer Induced by Treating Aplastic Anemia With Androgenic Agents?

*Pediatrics* 1974;53:764

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/53/5/764